Brainstorm Cell Therapeutics Inc. BCLI
0.97
0.02
2.11%
as of 25 Sep
- Market cap
- $7.0M
- P/E
- 0.0×
Follow BCLI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.03 | 0.02 | 0.03 | 0.06 |
+8 more quarters Free account |
Net Debt/EBITDA |
(0.35) | (0.65) | (0.43) | (0.05) | |
Debt/Assets |
160.03% | 176.03% | 94.62% | 7.32% | |
Debt/Equity |
(0.11) | (0.12) | (0.10) | (0.01) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.23 | 0.62 | 0.30 | 0.52 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.08) | (0.12) | (0.08) | (0.10) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
(1.05) | (1.00) | (1.08) | (0.70) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.05) | (1.00) | (1.08) | (0.70) | |
Free Cash Flow |
(0.89) | (1.32) | (0.74) | (1.10) | |
Working Capital |
(12.07) | (11.58) | (10.70) | (8.51) | |
Net Current Asset Value |
(12.07) | (11.58) | (10.70) | (8.56) | |
| Other line items | |||||
Quick Ratio |
0.01 | 0.01 | 0.01 | 0.01 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.08) | (0.12) | (0.08) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.13 | 0.09 | 0.07 | 0.06 | |
Average Payables |
6.05 | — | 6.20 | 5.56 | |
Average Assets |
1.68 | 2.16 | 1.43 | 1.70 | |
Average Common Equity |
(8.83) | (9.23) | (8.87) | (6.87) | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates